Significant reduction in SLC22A6 (OAT1) mRNA expression was defined in renal biopsy specimens from patients with different types of nephropathy, i.e., lupus nephritis, IgA nephropathy, focal glomerular sclerosis, membranoproliferative glomerulonephritis, membranous glomerulonephropathy, mesangial proliferative glomerulonephropathy, in comparison to the normal controls. Here, SLC22A6 is linked to kidney disorder.